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INTRODUCTION 
Chronic kidney disease refers to the permanent loss of renal 
function leading to impairment of excretory and endocrine functions of 
kidney. Signs and symptoms of chronic renal failure is termed as uremia. 
In chronic kidney disease patients major lipid abnormalities are 
decreased HDL cholesterol and increased triglyceride, which cause 
atherosclerosis resulting in Coronary artery disease. 
Chronic kidney disease causes hypertension, which is also a 
predisposing factor for atherosclerosis and coronary disease. 
In Chronic kidney disease patients cardiovascular diseases are the 
major cause of mortality and morbidity. 
Dyslipidemia accelerates the progression of Chronic kidney 
disease. 
Indian studies on lipid abnormalities in chronic kidney disease 
,such as, Sharma et al and Kundu et al found no hyperlipidemia whereas, 
Gupta et al and Das et al observed hypertriglyceridemia and reduced 
HDL cholesterol in Chronic kidney disease patients. In view of this 
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inconsistency and limited evaluation in southern part of India extended 
research on the topic is needed.  
Our study is presented to highlight the importance of dyslipidemic 
complications of CKD and early diagnosis can prevent the cardiovascular 
complications. 
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AIMS AND OBJECTIVES 
• To estimate various lipid profile abnormalities in Chronic 
Kidney Disease patients. 
• To identify the predominant lipid pattern abnormality in 
chronic Kidney Disease patients.  
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REVIEW OF LITERATURE 
HISTORICAL REVIEW 
• Charaka explained the different varieties of prameha or urinary 
affections in 2nd century. 
• Hippocrates has given detailed description of renal diseases. He 
diagnosed certain affections of the kidney by urine examination. 
• Jacob Henle (1840) showed urinary casts under the microscope and 
correlated them as the Nephritic Kidney at autopsy in 1847.1 
• In 1847, Piorry P.A. Coined the term UREMIA, the primary 
abnormality in renal insufficiency, namely the retention of urine in 
the blood.  This theory persisted into the 20th century, and the role 
of urea and other retained toxins was particularly emphasized.2 
• Frederick Wohler in 1882 synthesized urea in the laboratory. 
• Frederick and Akbar Mohammad (1849-84) noticed the 
relationship between hypertension and renal disease.3 
• Herman Strauss in 1912 described urea estimation in the evaluation 
of kidney disease. Otto Folin in 1912 improved on the method by 
introducing the colorimetric method. 
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• Franz Volhard in 1918 introduced the specific gravity 
concentration test into clinical work.3 
• Simillie noted the deleterious effects of potassium administration 
to uremic patients in 1915 and Boeher incriminated magnesium 
toxicity in many of the central nervous system manifestations of 
uremia. 
• In 1928 Openheimer and Fishberg first clearly distinguished 
hypertensive encephalopathy from uremia. 
NORMAL KIDNEY - Anatomy4 
 
The kidneys are paired retroperitoneal organs situated in the 
posterior part of the abdomen on each side of the vertebral column. 
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The upper pole of each kidney lies opposite to the 12th thoracic 
vertebra and the lower pole of each kidney lies opposite to the third 
lumbar vertebra. 
 
The weight of each kidney ranges from 125 to 170 gm. in adult 
man and 115 to 155 gm. in adult woman. In humans, the kidney is usually 
11 to 12 cm. in length 5.0 to 7.5 cm. in width and 2.5 to 3.0 cm in 
thickness. 
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Functions of the kidney 
The main function of the kidneys is the excretion of waste products 
derived from metabolism, toxic substances and some drugs. 
Kidneys also performs several other important functions which are 
essential in maintaining normal homeostasis. These are 
• Maintenance of fluid and electrolyte balance 
• Maintenance of acid-base balance. 
• Maintenance of normal blood pressure through renin-angiotensin 
system 
• Endocrine functions. 
1. Conversion of 25(0H)2 D3 to 1,25(OH)2 D3 occurs in kidney . 
2. Erythrpoietin production also takes place in kidney. 
3. Synthesis of prostaglandins which play an important role in 
renal auto regulation of blood flow. 
• Ammonia  formation  which  plays  important  role  in  maintaining  
acid  base balance. 
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CHRONIC RENAL FAILURE 
Chronic kidney disease5 
 
Definition 
1. Kidney damage for more than 3 months as defined by 
structural or functional abnormalities of the kidney, with or without 
decreased GFR, manifested by either, 
• Pathological abnormalities or, 
• Markers of kidney damage including abnormalities in the 
composition of the blood or urine or abnormalities in imaging tests. 
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2. GFR < 60ml/min/1.73m2 for  ≥ 3 months, with or without 
kidney damage. 
The presence of chronic kidney disease should be established based 
on presence of kidney damage and level of kidney function (glomerular 
filtration rate), irrespective of diagnosis. 
Among patients with CKD the stage of disease should be assigned 
based on the level of kidney function, irrespective of diagnosis according 
to the KDOQI CKD classification. 
 
GFR 
GFR is calculated using Cockcroft and Gaultformula6  
Estimated creatinine clearance in ml/min:  
(140-age) X Lean body weight /72X plasma creatinine (mg/dl)  
Multiplied by 0.85 for women. 
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Chronic renal failure is a syndrome, which results from progressive 
and irreversible destruction of nephrons regardless of the etiology, where 
the kidney is no longer able to maintain the biochemical homeostasis. The 
syndrome is complex and the biochemical changes and clinical signs are 
variable and mostly non-specific. 
Chronic renal failure may result from any destructive and 
progressive condition affecting both the kidneys.  It implies failure of 
both the glomerular and tubular functions. By convention ,acquired 
tubular defects or isolated congenital defects are not included in the 
consideration of  chronic renal failure. 
Chronic renal failure may be asymptomatic or symptomatic. 
Kidney has a tremendous reserve capacity. About 80% of renal function 
will be lost before the renal failure develops. 
Thus, the GFR usually would have fallen to about 40 ml per 
minute, before the blood urea nitrogen or creatinine levels raise above the 
upper limits of normal. Azotemia refers to the accumulation of 
nitrogenous waste products in the blood and is reflected as elevated blood 
urea nitrogen. 
‘Uremia’ is defined as symptomatic renal failure 
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Stages of chronic kidney disease5 
Stage Description. GFR ml/min /1.73m2
1 Kidney damage with normal or  ↑GFR > 90 
2 Kidney damage with mild ↓GFR 60-89 
3 Moderate ↓GFR 30-59 
4 Severe  ↓GFR 15-29 
5 Established Renal Failure <15(or dialysis ) 
 
Aetiology of chronic renal failure7 
The etiological spectrum of CRF differs somewhat in different 
parts of the world7 
Primary glomerulonephritis is the commonest cause of CRF in 
developing countries of the world, whereas diabetic glomerulosclerosis is 
emerging as the most common cause of CRF in developed countries 
where life expectancy of diabetics has increased considerably as a result 
of better diabetic care7 
Diabetic and hypertensive nephropathy are the leading underlying 
etiologies of both CRD and ESRD8. 
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Important causes of chronic renal failure. 
• Primary  glomerulonephritis 
• Secondary glomerulopathy –systemic disease 
• Interstitial renal disease. 
• Hypertensive renal disease 
• Obstructive  nephropathy 
• Heredo-familial renal disease 
Pathophysiology of chronic renal failure 
Progressive Nephron loss and adaptations7 
In CRF the number of nephrons goes on diminishing with passage 
of time. As nephrons continue to be lost, the remaining undamaged or less 
severely damaged nephrons undergo certain changes. Experimental 
studies have shown that the single nephron GFR in remaining intact 
nephrons, tends to increase and they undergo compensatory hypertrophy. 
At this stage of disease, GFR can be maintained normal, despite reduced 
number of nephrons until the limits of increase of single nephron GFR is 
reached. 
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These beneficial compensatory adaptations in residual renal 
function ultimately have harmful systemic and renal effects. These have 
been termed as trade off hypothesis9. 
There is some evidence that supports the trade –off hypothesis. The 
adaptive increase in phosphate excretion per nephron that typically occurs 
in CRD is thought to be mediated at least in part by parathormone, and 
the levels of this hormone have been found to rise progressively 
throughout the course of CRD. The Consequence of this secondary 
hyperparathyroidism however extends far beyond the promotion of 
increased fractional phosphate excretion rates. 
Middle molecule hypothesis10. 
The discrepancy between the severity of symptoms and the degree 
of azotemia seems to be most marked in patients who are treated with 
maintenance peritoneal dialysis.  
Despite high BUN and serum creatinine levels, the symptoms of 
uremia are mild  and  peritoneal  dialysis  patients  may  be  less  prone  to  
developing  peripheral neuropathy than are hemodialysis patients. 
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These observations suggest that toxicity is related to the 
accumulation of higher molecular weight substances, which are cleared 
more readily by peritoneal dialysis, than by hemodialysis. 
The peritoneal membrane is more permeable to solutes of middle 
molecular weight11 (Aproximately 500 to  3000 daltons) compared  to 
hemodialysis membranes. The middle molecule (MM) hypothesis 
predicts that shortening the duration of dialysis will jeopardize the 
removal of these compounds, despite the same clearance of smaller 
solutes. 
The MM hypothesis has a number of shortcomings. First, the 
efficiency with which dialysis corrects the uremic syndrome argues in 
favour of low molecular weight solutes, playing the pathophysiologically 
pre- eminent role. 
Second, most solutes are of low molecular weight and are not of 
MM size12. 
In summary the MM hypothesis remains controversial, despite a 
great deal of research. 
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Clinical Features 
Fluid and electrolyte disturbances 
• Volume expansion 
• Hyponatremia, Hyperkalemia 
• Hyperphosphatemia 
Endocrine - Metabolic disturbances13,14,15 
• Secondary hyperparathyroidism, Adynamic bone disease 
• Vit. D deficient osteomalacia16 
• Hyperuricemia, Hypertriglyceridemia 
• Increased Lp (a) levels, Decreased high density lipoprotein 
level 
• Malnutrition 
• Amenorrhea ,infertility and sexual dysfunction 
• α2 macroglobulin associated amyloidosis 
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Neuromuscular Disturbances 
• Fatigue, Muscular rigidity 
• Peripheral neuropathy, Restless leg syndrome 
• Myoclonus17 
• Seizures, Coma18,19, Muscle cramps 
• Dialysis disequilibrium syndrome 
• Sleep disorders, Headache, Impaired mentation  
• Lethargy, Myopathy, Asterixis20 
Cardiovascular and pulmonary complication 
• Arterial hypertension21,22,23, Pericarditis24 
• Hypertrophic or dilated cardiomyopathy, Uremic lung25,26 
• Congestive heart failure or pulmonary edema 
• Accelerated atherosclerosis, Hypotension and arrhythmias 
• Vascular calcification27 
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Dermatologic Disturbances28,29 
• Pallor, Hyperpigmentation 
• Pruritus, Ecchymoses 
• Fibrosing dermopathy, Uremic frost 
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Gastro Intestinal disturbances30,31 
• Anorexia, Nausea and vomiting 
• Gastrointestinal bleeding, Idiopathic ascites 
• Gastroenteritis, Peptic ulcer, Peritonitis 
Hematologic and Immunologic disturbances32 
• Anemia, Leukopenia, Thrombocytopenia 
• Lymphocytopenia, Increased susceptibility to infection 
• Bleeding diathesis 
Management of Chronic Renal Failure 
The optimal timing of therapy is usually well before a measurable 
decline in GFR and certainly, before CKD is established. 
1. Diet  
 - Protein restriction 0.6-0.75g/kg/day 
 - Low salt 60-80mmol/day 
2. Blood pressure control  
 - Bp<130-135/80-85mmHg if proteinuria <1g/24 hr 
19 
 
 - Bp<125/75 mmHg if proteinuria >1g/24 hr 
3. Proteinuria  
 - to  reduce to <1g/24hr, use an ACE inhibitor or angiotensin 
  receptor antagonist 
4. Glycemic control in DM  
 - Hb AIC < 7% 
5. Dyslipidemia  
 -Control individual lipid fractions 
6. Smoking  
 - cessation 
7. Alcohol  
 - Restriction to less than 2 drinks per day. 
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LIPOPROTEIN METABLISM 
Lipoproteins are complexes of lipids and proteins that play a main 
role in the transport of cholesterol, triglycerides and fat soluble vitamins. 
Because the lipids are hydrophobic they need a transporter in the form of 
proteins to transport them through body fluids across tissues. These 
lipoproteins are necessary for transport of triglycerides, cholesterol and 
fat soluble vitamins from the liver to peripheral tissues; and transport of 
cholesterol from peripheral tissues to the liver. 
 
The structure of lipoprotein is basically a neutral lipid core 
surrounded by a coat shell. Lipid core constituents are triacylglycerol  and 
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cholesteryl ester, whereas the shell is formed by phospholipids and 
cholesterol. Phospholipids and cholesterol are amphiphilic that’s why, 
they are exposed on the surface of the lipoproteins and triacylglycerol and 
cholesteryl ester are hydrophilic, so they are placed in the core. 
Classification of lipoproteins 
Five major classes of lipoproteins are identified in human plasma, 
based on their separation according to density by electrophoresis. 
1. CHYLOMICRONS: They are synthesised in the intestine 
and transported exogenously i.e dietary triacylglycerol to various tissues. 
They constitute highest quantity of lipid, which have low density and 
larger size than that of proteins, and lowest quantity of proteins. So the 
chylomicrons are least in density and largest in size, among the 
lipoproteins 
2. VERY LOW DENSITY LIPOPROTEINS: They are 
produced in the liver and intestine and are responsible for the transport of 
endogenously synthesized tiacylglycerols. 
3. LOW DENSITY LIPOPROTEINS: They are from VLDL in 
the blood circulation. They transport cholesterol from liver to other 
tissues 
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4. HIGH DENSITY LIPOPROTEINS: They are mostly 
synthesized in the liver. Three different fractions of HDL can be 
identified by ultracentrifugation, HDL1, HDL2 and HDL3. 
HDL particles transport cholesterol from peripheral tissues to the 
liver. This transport is called as reverse cholesterol transport. 
5. FREE FATTY ACIDS: They are in the circulation as a 
bound form to albumin and this lipoprotein cannot be separated by 
electrophoresis. 
Classification of Lipoproteins: 
Lipoprotein Density g/ml 
Size 
nm 
Electrophoretic
pattern 
mobility 
Major 
apoproteins 
Other 
apoproteins 
Chylomicrons 0.93 75-
1200 
Origin Apo B-48 A-1, A-IV,  
C-I, C-II,  
C-III 
Chylomicron 
remnants 
0.930-
1.006 
30-80 Slow pre-β Apo B-48 E, A-I,  
A-IV, C- I, C-
II, C-III 
VLDL 0.930-
1.006 
30-80 Pre-β Apo B-100 E, A-I, A-II, 
A-V, C-I,  
C-II, C-III 
IDL 1.006-
1.019 
25-35 Slow pre-β Apo B-100 E, C-I, C-II, 
C-III 
LDL 1.019-
1.063 
18-25 β Apo B-100  
HDL 1.063-
1.210 
5-12 alpha Apo A-I A-II, A-IV, 
  E, CIII 
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Transport of dietary lipids: (exogenous pathway) 
 
In the intestine, triglycerides are acted upon by lipases and 
emulsified with bile acids to form micelles. 
 Chylomicrons are formed by packaging of triglycerides, 
cholesteryl esters, cholesterol and retinyl esters along with ApoB48. This 
nascent chylomicrons are secreted into the intestinal lymph and from 
there, they directly enter the blood circulation through the thoracic duct.  
The chylomicron particles are metabolized by lipoprotein lipase 
(LPL), which are present over the capillary endothelial walls of adipose 
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tissue, heart and skeletal muscle. During the metabolism of triglycerides 
by the lipoprotein lipase free fatty acids are released. 
ApoCII is the co-factor for the lipoprotein lipase which is 
transferred to the chylomicrons from the HDL. After the metabolism by 
the lipoprotein lipase the chylomicrons progressively shrinks in size and 
are called chylomicron remnants. The cholesterol ester and triglycerides 
are hydrolysed and the cholesterol, phospholipids, apoproteins C and E 
are transferred to the HDL. 
 Finally chylomicron remnants are taken up by the liver, where 
apoE acts as a ligand for LDL receptors in the liver. So usually 
chylomicrons or chylomicron remnants are cleared from the circulation 
within 12 hours.  
Transport of hepatic lipids: (endogenous pathway)33 
VLDL particles have ApoB100 as co-factor and they have higher 
ratio of cholesterol to triglyceride as compared to that of the 
chylomicrons.  
VLDL is formed by the packaging of ApoB100,cholesteryl esters 
and phospholipids. This packaging of nascent chylomicron requires 
microsomal triglyceride transfer protein (MTP)34.  
25 
 
 
VLDL are metabolised by the lipoprotein lipase35 present in the 
muscle and adipose tissue. 
 VLDL is the precursor of IDL and, from IDL, VLDL is formed. 
Each LDL is derived from only one VLDL because the apoprotein of 
VLDL, ApoB100 is conserved during this transformation.  
IDL can enter two sets of metabolism, either it can be taken up by 
the liver, directly through the LDL receptors36 or, it can be metabolized 
by lipoprotein lipase and form LDL. 
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HDL Metabolism and Reverse Cholesterol Transport: 
 
 
HDL is synthesized and secreted by the liver. Nascent HDL is 
discoidal shaped and it consists of phospholipid, cholesterol and ApoA. A 
plasma enzyme Lecithin: Choleserolacyltransferase(LCAT) gets attached 
to the disk and subsequently ApoA1, the activator of LCAT, binds to 
LCAT. This binding is responsible for the conversion of phospholipids 
and cholesterol into lysolecithin and cholesteryl esters, respectively. 
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Lysolecithin is transferred to plasma albumin and cholesteryl ester 
being nonpolar is moved into the interior, from the surface. In this 
process, HDL becomes spherical, containing polar lipids and apoproteins.  
Thus, LCATsystem helps in the transport of unesterified 
cholesterol from lipoproteins and tissues.  
The class B scavenger receptor B1(SR-B1) is identified as the 
HDL receptor in the liver. ApoA1 binds to the SR-B1 and the cholesteryl 
esters are delivered to the liver cells and apo A1 is released in the process 
to form pre β HDL, the most potent form of HDL.  
This transport of cholesterol from the tissues to the liver is known 
as reverse cholesterol transport. 
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LIPID PROFILE IN CHRONIC RENAL FAILURE 
ALTERATION OF LIPIDS AND LIPOPROTEINS IN CKD 
Quantitative changes in the lipid pattern. 
 Plasma triglycerides are elevated, because of  
• Decreased clearance of VLDL from the plasma and 
decreased clearance of the IDL.         
• Decreased clearance of chylomicrons from the plasma. 
Plasma cholesterol is normal or reduced , but occasionaly in cases 
of ESRD, plasma cholesterol levels may be increased 
Plasma LDL levels are usually normal or may be occasionally 
increased in ESRD. 
Plasma HDL is consistently reduced 
HDL-3 To HDL-2 ratio is impaired in Chronic kidney 
disease,39,40,41,42,43,44,45. 
Altered composition of lipoproteins.39,41,42,43 
In VLDL, its cholesterol content is relatively increased and the 
triglyceride is relatively decreased. 
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In LDL, its cholesterol content is relatively decreased and the 
triglyceride is relatively increased , in contrast to that of the VLDL. 
In HDL, its cholesterol content is relatively decreased, its 
cholesteryl ester content is relatively decreased whereas, its triglyceride 
content is relatively increased. This changes indicates the redistribution of 
cholesterol from HDL to VLDL and IDL, defective removal of 
triglycerides from HDL and LDL. 
 
Alteration of apoprotein levels.39 
Decreased levels of Apo AI and Apo AII 
Decreased levels of Apo E 
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Increased levels of Apo  CIII 
Decreased ratio of Apo CII to Apo CII.  
These apoprotein changes are believed to be the reasons, for the 
possible changes in lipid profile of the chronic kidney disease, because 
the changes in apoproteins precedes that of the lipid changes in early 
renal insufficiency.39 
PLASMA LIPID AND LIPOPROTEIN CHANGES IN CHRONIC 
KIDNEY DISEASE 
PROTEIN CHANGE EFFECT ON PLASMA LIPIDS/ LPs 
Apo AI ↓ ↓  HDL 
LCAT ↓ ↓HDL Ch ↓  HDL-2/HDL-3 
CETP ↑ ↓HDL Ch ↑ HDL-TG 
ACAT ↑ ↑VLDL Ch ↓HDL Ch 
LPL ↓ ↑  TG 
VLDL receptor ↓ ↑ VLDL ↑TG 
HEPATIC LIPASE ↓ ↑ IDL   ↑TG  ↑ HDL-TG   ↑LDL-TG 
LRP ↓ ↑IDL ↑ CM remnants 
ApoCII/CIII ↓ ↑TG 
Preβ HDL ↑ ↑TG 
HEPATIC  DGAT ↓ ↓  VLDL-TG 
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ALTERATION OF THE HDL METABOLISM IN CHRONIC KIDNEY 
DISEASE 
HDL levels are decreased in chronic renal failure with alteration  in 
composition of HDL by increase in triglyceride level and decrease in 
cholesterol level. 
This abnormalities are due to dysregulation of the following 
proteins, 
Apo AI and ApoAII50 :  Their levels are reduced in chronic renal 
failure and the possible reason for the reduction is downregulation of 
ApoAI gene expression.  
This proteins being the structural constituents of the HDL, decrease 
in their levels lead to decrease in the levels of the HDL46. 
LCAT:  Their levels are consistently decreased in chronic kidney 
disease47,48,44. 
The reason for the decreased levels of LCAT in chronic kidney 
disease are, 
• decreased hepatic production  
• inhibition by unknown uremic toxin 
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CETP:  Their levels are increased in chronic kidney disease. 
Proteinuria increases the level of CETP49,50 
SRB-1: They are useful in transport of HDL containing cholesteryl 
esters and triglycerides 
In chronic renal failure, SRB-1 expression is dysregulated51,46. 
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ACAT: It is the enzyme for esterification of intracellular 
cholesterol, but HDL cholesterol transport from the peripheral  tissues 
depend on the deeseterification of the cholesteryl esters52. 
In chronic kidney disease, ACAT-2 levels are found to be increased 
which can decrease the levels of HDL in the plasma 
 METABOLISM OF TRIGLYCERIDES IN CHRONIC RENAL 
FAILURE39,41,57 
I. Decreased  Catabolism 
A. Decreased activity of lipolytic enzymes 
 1. Lipoprotein lipase due to 
• Insulin deficiency 
• Inhibitors in uraemic plasma 
• Reduced apo C-II/apo C-III ratio 
 2. Hepatic Triglyceride lipase. 
 3. Lecithin cholesterol acyl transferase (LCAT) 
B. Alteration of lipoprotein substrate 
C. Decreased carnitine level. 
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D. Decreased beta oxidation of free fatty acids. 
E. Triglyceride enriched LDL 
F. Altered apolipoprotein composition 
TRIGLYCERIDE METABOLISM IN CKD 
 
II. INCREASED ApoC-III/ApoE In IDL, LDL 
III. INCREASED TRIGLYCERIDE PRODUCTION 
• Increased dietary carbohydrates 
• Uptake from glucose due to immune resistance to 
insulin45, 
• Hyperinsulinemia 
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METABOLISOM OF CHOLESTEROL IN CHRONIC RENAL 
FAILURE: 
Plasma cholesterol levels are normal or decreased but occasionally 
can be increased. 
Synthesis of cholesterol:  HMG CoA reductase is the rate limiting 
enzyme in the synthesis of cholesterol.  
No considerable change in the activity of HMG CoA is found in 
the chronic kidney disease but, proteinuria can modify HMG CoA 
expression.54 
Catabolism of cholesterol: The enzyme 7α reductase is the rate 
limiting enzyme in the cholesterol conversion to bile acids55. 
The LDL receptor protein levels are not altered in chronic kidney 
disease, so the LDL receptor mediated cholesterol uptake is not altered. 
Their levels are not considerably increased in chronic renal failure. It is 
noted that proteinuria in early renal insufficiency can simulate nephrotic 
syndrome and can lead onto hypercholesterolemia and increased LDL 
levels. 
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CLINICAL SIGNIFICANCE OF RENAL DYSLIPIDEMIA 
Cardiovascular disease is the leading cause of death in patients 
with ESRD and lipid abnormalities present in CRF patients contributing 
to cardiovascular mortality.56, 57 
In  the  Monitored  atherosclerosis  regression  Study  (MARS)58  a  
number  of correlation were found between the markers of Apo B 
containing lipoproteins and the annualized rate of atherosclerotic change 
in the distal common carotid artery wall which was determined by high 
resolution B mode ultra sound. 
Progression of common carotid atherosclerosis significantly 
correlated with the progression of coronary artery disease as measured by 
quantitative coronary angiography. 
The results of MARS study provided further evidence for the 
impact of triglyceride rich lipoproteins in progression of CAD. 
Recent data obtained in hemodialysis patients demonstrated 
reduced capacity of the HDL to prevent LDL oxidation in vitro. 
So combined hyperlipidemia with elevated triglyceride with low 
HDL cholesterol level reflects probably more atherogenic condition than 
does isolated elevation of LDL cholesterol. 
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Small LDL particles present in patient receiving hemodialysis also 
contributes to cardiovascular mortality. 
Lipid abnormalities probably represent one of several potentially 
correctable cardiovascular risk factors associated with CRF59,60,61.  
DYSLIPIDEMIA AND PROGRESSION OF RENAL DISEASE IN 
CKD PATIENTS62,63 
Experimental studies have provided a clear link between 
hyperlipidemia and kidney damage in animals but there is only limited 
evidence to suggest that, lipids contribute to progression of renal disease 
in man. 
Lipid abnormalities directly contribute to glomerelosclerosis and 
tubulointerstitial injury and that correction of lipid abnormalities 
associated with renal disease will slow the progression of CRF. 
TREATMENT OF DYSLIPIDEMIA IN CKD 
Rationale for lipid lowering treatment in ESRD61. 
The quantities of abnormal lipoprotein particles in uremia and their 
associated coronary disease are underestimated by conventional 
cholesterol measurement. 
38 
 
Beneficial effects of lipid lowering therapy in ESRD are likely but 
the effectiveness of lipid lowering on the reduction of cardiovascular end 
points remain elusive 
Statins: These drugs are shown to be highly effective in reducing 
LDL cholesterol concentrations in both diabetic and non-diabetic patients 
with CRF. Statins also lower the levels of atherogenic IDL64. 
 
A  meta  analysis  of  four  randomized  trials65,66such as, 4S,  
CARE, AFCAPS/ Tex CAPS, 67 comparing HMG – COA reductase 
inhibitors to control included , 817 participants found that, HMG-COA 
reductase inhibitor treatment was associated with, 
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1) 20% decrease in total cholesterol, 5% increase in HDL 
cholesterol, 28% decrease in LDL cholesterol and 13% decrease 
in triglycerides. 
2) 31% decrease in major coronary events and a 21% decrease in 
all cause mortality. 
3) Similar risk reduction in women and men. 
Unexpectedly the risk of stroke was also reduced by 19-32%  by 
HMG-COA reductase inhibitor treatment. 
Fibric Acid Derivatives : These drugs improve lipoprotein lipase 
activity and inhibit hepatic synthesis of VLDL cholesterol,  resulting in 
reduction of triglyceride and an increase in HDL cholesterol68. 
Lipid lowering therapy in patients with renal insufficiency may 
help to slow the rate of renal disease progression and reduces the risk of 
cardiovascular mortality and morbidity. 
TREATMENT STRATEGY IN STAGE V CKD: 
For adults with stage V CKD and fasting triglyceride > 500mg/dl, 
that cannot be corrected by removing an underlying cause, treatment with 
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therapeutic life style changes and triglyceride lowering agent should be 
considered. 
For adults with stage V CKD and LDL ≥ 100 mg/dl treatment 
should be considered to reduced LDL < 100 mg/dl. 
For adults with stage V CKD and non-HDL cholesterol ≥ 130 
mg/dl, treatment should be considered to reduce non-HDL cholesterol to 
<130 mg/dl. 
The National kidney foundation task force on CVD concluded that 
the incidence of ACVD is higher in patients with CKD compared to the 
general population. The task force concluded that patient with CKD 
should be considered to be in the highest risk category i.e. CHD risk 
equivalent, for risk factor management. 
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MATERIALS AND METHODS: 
Setting 
The study was conducted in Government Mohan 
Kumaramangalam Medical College, Salem. 
Study Design: 
Cross- sectional study. 
Period of Study 
July 2010 to June 2012 
Sample Size:  
50 Cases; 50 Controls 
Study Population: 
Patients admitted in medicine wards of Government Mohan 
Kumaramangalam Medical College, Salem. 
Ethical Committee Clearance:  Obtained 
Conflict Of Interest: Nil 
Financial Support: Nil 
42 
 
Case Definition: 
Chronic kidney disease5 
• Kidney  damage  for  ≥ 3  months  as  defined  by  structural  or  
functional abnormalities of the kidney, with or without 
decreased GFR manifested by either, 
Pathological abnormalities or, 
Markers of kidney damage including abnormalities in the 
composition of the blood or urine or abnormalities in imaging tests. 
• GFR < 60ml/min/1.73m2 for ≥ 3 months, with or without 
kidney damage. 
The presence of chronic kidney disease should be established based 
on presence of kidney damage and level of kidney function (glomerular 
filtration rate), irrespective of diagnosis. 
Among patients with CKD the stage of disease should be assigned 
based on the level of kidney function, irrespective of the diagnosis 
according to the KDOQI CKD classification. 
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Stages of the CKD: 
Stage Description. GFR ml/min /1.73m2
1 Kidney damage with normal or  ↑GFR > 90 
2 Kidney damage with mild ↓GFR 60-89 
3 Moderate ↓GFR 30-59 
4 Severe  ↓GFR 15-29 
5 Established Renal Failure <15(or dialysis ) 
 
The cases are diagnosed with the help of the following criteria: 
Clinical Criteria: 
• Anaemia of chronic renal failure  
• Hypertension 
• Uremic symptoms – Three months duration 
Biochemical Criteria: 
• Elevated blood urea & serum Creatinine 
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Ultra sonographic Criteria: 
 
• Contracted kidney 
• Increased cortical echogenicity 
• Loss of cortico- medullary differentiation 
Inclusion Criteria: 
• Patients between age group of 15 to 80 years with chronic  
kidney disease. 
• Patients with established chronic kidney disease were selected 
irrespective of the etiology. 
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• Established chronic kidney disease was ensured by radiological 
evidence or biochemical evidence for more than 3 months 
Exclusion Criteria: 
• Patients with known h/o diabetes mellitus and patients with 
Diabetic kidney disease , with elevated random blood sugar values of 
>200mg% were excluded. 
• Ischemic heart disease on treatment already, were excluded. 
• Severe comorbid conditions like pneumonia, alcoholic Liver 
disease and hypotension were excluded. 
• Those who are taking Beta blocker and thiazide diuretics at time 
of study were excluded. 
• Patients with H/o intake of anti cholesterolemic agentswere 
excluded. 
• Patients with H/O cigarette smokingwere excluded. 
• Patients with the features of hypothyroidism and obstructive 
Liver disease were excluded. 
• Patients with previous H/o hemodialysis and peritoneal dialysis 
were excluded. 
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Controls: 
Age matched and sex matched  50 non- smoking healthy 
volunteers 
Methods: 
Both cases and controls are evauated with: 
• Clinical history and physical examination 
• Blood- urine,  sugar 
• Serum creatinine 
• Urine routine 
• Complete blood count 
• X ray chest PA view 
• USG abdomen 
• Serum fasting lipid profile 
• ECG 
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Lipid profile: 
Blood samples were obtained on one occasion from antecubital 
venepuncture after an overnight fast (12hrs) from all patients. 
• Triglycerides were estimated by enzymatic colorimetric method. 
• TC was estimated using enzymatic method. 
• HDL was estimated by phosphotungstate method. 
• LDL cholesterol was calculated by Friedewald’s equation. 
LDL = TC – triglycerides/ 5 - HDL 
AccordingtoNationalCholesterolTreatmentProgramAdultTreatment
PanelIIIguidelines, 
Lipid classification according to ATP III38 
Lipoproteins Levels Category 
LDL –C (mg/dl)  
< 100 Optimal 
100-129 Near or above optimal 
130-159 Borderline high 
160-189 High 
>190 Very high 
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Lipoproteins Levels Category 
Total cholesterol  (mg/dl)  
< 200 Desirable 
200-239 Borderline high 
> 240 High 
HDL – C (mg/dl)  
< 40 Low 
≥60 High 
Triglycerides(mg/dl)  
< 150 Normal 
150-199 Border line high 
200-499 High 
>500 Very high 
 
And the normal values of lipoproteins according to ATP III 
classification are, 
LDL cholesterol    <130mg/dl (with 2+ risk factors) 
HDL cholesterol >40 mg/dl 
Triglycerides <150 mg/dl 
Total cholesterol <200 mg/dl. 
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Statistical Analysis 
The data were analysis using SPSS (Statistical Package for Social 
Science) Ver 16.01. The data collected were scored and analyzed, 
Continues variables were presented as means with Standard deviation 
(sd) and categorical variables were presented as frequency and 
percentages. Student t-test and analysis of variance (ANOVA) were used 
for testing the significance of all the variables (Mean & Sd) in both the 
group. Chi-square test was used to compare proportions. All the 
Statistical results were considered significant at P value < 0.05. 
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OBSERVATION AND RESULTS 
Table - 1 : Age Distribution among Cases and Controls 
Age  Group 
(in Years) 
CASE CONTROL 
Number % Number % 
15 -25 3 6.00 0 0 
25-35 5 10.00 0 0 
35-45 13 26.00 4 8.00 
45-55 12 24.00 39 78.00 
55-65 15 30.00 7 14.00 
65-75 2 4.00 0 0 
Mean±sd 48.38 ± 13.05 51.66 ± 4.14 
t-value 1.69 
Df 98 
p-value 0.09 (Not Significant) 
 
The mean age of the patients were 48.3 years and mean age of the 
controls were 51.6years.There was no significant difference between the 
study cases and controls in the age. p value (0.09) not significant, hence 
they are comparable. 
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Table - 2 : Sex distribution among Cases and Controls 
Sex 
CASE CONTROL 
Number % Number % 
Male 33 66.00 30 60.00 
Female 17 34.00 20 40.00 
Total 50 100 50 100 
Chi-square value 0.39 
Df 1 
(p value) 0.53 (Not Significant) 
 
There was no significant difference between study group and 
controls regarding the sex distribution, p value (0.53). Hence they are 
comparable. 
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Table - 3 : Distribution of HDL among Cases and Controls 
HDL CASE CONTROL 
Mean 38.86 54.04 
Sd 8.04 10.74 
Range 24 - 57 37 - 78 
t-Value 8.00 
Df 98 
p-value 0.000 (Significant) 
 
In our study, HDL showed a significant reduction in CRF cases, 
compared with controls. The mean HDL in cases were 38.8 mg/dl and 54 
mg/dl in controls. The difference was statistically significant with a p 
value of 0.0001. 
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Table - 4 : Distribution of LDL among Cases and Controls 
LDL CASE CONTROL 
Mean 110.08 101.62 
Sd 45.10 23.76 
Range 38 - 217 50 - 155 
t-Value 1.17 
Df 98 
p-value 0.24 (Not Significant) 
 
LDL Cholesterol was high in cases, compared to controls, but the 
difference was not significant statistically. The mean LDL in cases was 
110 mg/dl and 101.6 mg/dl in controls. The p value was (0.24), not 
significant. 
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Table - 5 : Distribution of TGL among Cases and Controls 
TGL CASE CONTROL 
Mean 147.68 127.86 
Sd 61.57 27.23 
Range 36 - 278 72 – 212 
t-Value 2.09 
Df 98 
p-value 0.04 (Significant) 
 
In our study, triglyceride showed a significant increase in CRF 
cases, compared with controls. The mean triglyceride in cases were 147.6 
mg/dl and 127.8 mg/dl in controls. The difference was statistically 
significant with a p value (0.04). 
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Table - 6 : Distribution of TC among Cases and Controls 
TC CASE CONTROL 
Mean 164.02 176.34 
Sd 39.90 24.37 
Range 72 -263 90 - 231 
t-Value 1.86 
Df 98 
p-value 0.07 (Not Significant) 
 
Total Cholesterol was decreased in cases compared to controls, but 
the difference was not significant statistically. The mean Cholesterol in 
cases was 164mg/dl and176.3 mg/dl in controls. The p value (0.07) was  
not significant. 
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Table - 7 : Distribution of TC/HDL among Cases and Controls 
TC/HDL CASE CONTROL 
Mean 4.33 3.42 
Sd 1.09 0.95 
Range 1.57  – 7.07 1.50  - 5.51 
t-Value 4.46 
Df 98 
p-value 0.000 (Significant) 
 
Total Cholesterol /HDL ratio was increased in cases compared to 
controls, and the difference was significant statistically. The mean Total 
Cholesterol/HDL ratio was 4.3 in cases and 3.4 in controls. The p value 
(0.0001) was significant. 
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Table - 8 :  
Sexwise  percentage  distribution  of  staging  of  kidney diseases. 
Staging 
Male Female Total 
Number % Number % Number % 
     III 7 21.20 1 5.80 8 16.00 
     IV 12 36.40 8 47.10 20 40.00 
     V 14 42.40 8 47.10 22 44.00 
Total 33 100 17 100 50 100 
Chi- 
square 
2.02  
Df 2 
p-value 0.364 (Not Significant) 
 
The above table, shows the sexwise relation of the stages of CKD 
patients. Since there were no study group belong to stage I and stage II 
they were not included in the table. Among the three stages the sex 
differences were not statistically significant (P>0.05). Among the total 
cases, the stage V had more patients than other 2 stages. 
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Table - 9 : Stagewise comparison of C.K.D. and lipid abnormalities 
Variable Stages N Mean Sd F-value p-value 
HDL 3 8 38.38 8.38 0.10 0.90 * 
4 20 38.40 7.46 
5 22 39.45 8.74 
LDL 3 8 111.75 37.40 0.11 0.90* 
4 20 106.45 55.53 
5 22 112.77 45.09 
TGL 3 8 121.88 33.66 0.86 0.43* 
4 20 154.80 62.31 
5 22 150.59 67.85 
TC 3 8 156.75 37.84 0.23 0.79* 
4 20 162.80 45.55 
5 22 167.77 36.37 
TC/HDL 3 8 4.08 0.43 0.24 0.79* 
4 20 4.36 1.32 
5 22 4.37 1.04 
 
*Not significant 
67 
 
The mean HDL in stage III, IV, V patients were 38.38, 38.4, 39.45 
respectively and their S.D. are 8.3, 7.4, 8.7 respectively. The mean LDL 
in stage III, IV, V patient are 111.7, 106.4, 112.8 respectively and their 
S.D. were 37.4, 55.5, 45 respectively. The mean TGL value in stage III, 
IV, V were 121.8, 154.8, 150.5 respectively and their S.D were 33.6, 
62.3, 67.8. The mean TC in stage III, IV, V patient were 156.7, 162.8, 
167.7 respectively and their standard deviation were 37.8, 45.5, 36.3. The 
mean TC/HDL ratio in stages III, IV, V were 4, 4.3, 4.3 respectively and 
standard deviation were 0.4, 1.3, 1.4. From this table, the HDL, TGL, 
LDL, TC, TC/HDL ratio value in stages III, IV, V of CKD are not 
statistically significant (P>0.05). 
In other words, the intergroup variability of various stages of lipid 
abnormality are not statistically significant. 
  
 Chart - 
 
4
10
1
14
1
18
M
ea
n 
Sc
or
e
9 : Stagew
0
20
0
60
80
0
20
0
60
0
HD
CKD St
ise comp
 
L L
ages wit
arison o
DL T
h HDL, L
III IV
f C.K.D. 
C/HDL
DL, TC/H
V
and lipid
TGL
DL, TGL
 abnorma
TC
, TC
68 
lities 
 
69 
 
Table - 10 : Analyses and assessment of classification of HDL level 
among the C.K.D. cases stage wise. 
HDL 3 4 5 TOTAL 
 N % N % N % N % 
Low 5 62.50 14 70.00 12 54.50 31 62.00 
High 
 
3 37.50 6 30.00 10 45.50 19 38.00 
Total 8 100 20 100 22 100 50 100 
Chi-square 1.06   
df 2   
p-value 0.59 (Not Significant)   
 
Only stage IV had maximum number of low HDL levels,14 
patients (28%)  
31 patients (62 %) had HDL levels<40mg/dl 
19patients (16.6%) had HDL levels >40mg/dl.  
The association was not significant. (p value 0.59) 
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Table - 11 : Analyses and assessment of classification of LDL level 
among the C.K.D. cases stage wise. 
 3 4 5 TOTAL 
LDL N % N % N % N % 
Optimal 4 50.00 12 60.00 8 36.40 24 48.00 
Near 
Optimal 
1 12.50 2 10.00 6 27.30 9 18.00 
Borderline 
high 
2 25.00 2 10.00 6 27.30 10 20.00 
High 1 12.50 1 5.00 2 9.10 4 8.00 
Very.high 0 0 3 15.00 0 0 3 6.00 
Total 8 100 20 100 22 100 50 100 
Chi-
square 
9.77   
df 8   
p-value 0.28 (Not Significant)   
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Analyses and assessment of classification of LDL level among the 
C.K.D. cases stage wise. 
Only stage IV had very high LDL levels 
24 (48%) patients had optimal LDL levels(<100mg/dl), 
 9 (18%) patients had near optimal LDL levels, (100-129mg/dl) 
10(20%) patients had borderline high.(130-155mg/dl) 
4patients had high (160-189mg/dl) and 3 patients had very High 
(≥190mg/dl) values. p-value (>0.05), the association was not statistically 
significant.  
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Table - 12 : Analysis and assessment of classification of TC level 
among the C.K.D. cases stage wise. 
 3 4 5 TOTAL 
TC N % N % N % N % 
Desirable 6 75.00 17 85.00 17 77.30 40 80.00 
Borderline 
High 
2 25.00 2 10.00 4 18.20 8 16.00 
High 0 0 1 5.00 1 4.50 2 4.00 
Total 8 100 20 100 22 100 50 100 
Chi-square 1.42   
df 4   
p-value 0.09 (Not Significant)   
 
Stage V had the maximum number of borderline high patients 
40 patients (80%) had desirable TC levels (<200mg/dl) 
8patients (16%) had borderline high TC levels,(200-239mg/dl) 
2 patients(2%) had high TC levels(≥240mg/dl). 
The association was not statistically significant. P value(>0.05) 
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Table - 13 : Analysis and assessment of classification of TGL level 
among the C.K.D. cases stagewise. 
 3 4 5 TOTAL 
TGL N % N % N % N % 
Normal 7 87.50 11 55.00 13 59.10 31 62.00 
Borderline 
High 
1 12.50 3 15.00 4 18.20 8 16.00 
High 0 0 6 30.00 5 22.70 11 22.00 
Very 
High 
- - - - - - - - 
Total 8 100 20 100 22 100 50 100 
Chi-square 3.51   
df 4   
p-value 0.48 (Not Significant)   
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Analysis and assessment of classification of TGL level among the 
C.K.D. cases stagewise. 
Stage IV had 6 high triglyceride patients(12%) and Stage V had 5 
high triglyceride patients(10%). 
31 patients (62%) had normal TG values (<150mg/dl) 
8 patients (16%) had borderline TG values, (150-199mg/dl) 
11 patients (22%) had high TG values (200-499mg/dl),  
No patients had very high TG levels 
The association is not significant (p value 0.48) 
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DISCUSSION 
This study was done to identify the lipid abnormalities that occur in 
the CKD patients admitted in Govt. Mohan Kumaramangalam Medical 
College, Salem 
A total of 50 cases who fulfilled the inclusion and exclusion 
criteria CRF, were included in the study. 50 age and sex matched healthy 
controls were taken for comparing the lipid profile. 
Among 50 cases the mean age was 48. 38 yrs and the mean age of 
controls was 51.66 yrs. There was no significant difference between cases 
and controls with regard to the age. (P value –0.09). So they can be 
compared. 
There were 27 males and 13 females in the study group. Among 
the 50 controls, 30 were males and 20 were females. There was no 
significant difference between cases and controls as far as sex is 
concerned. (Pvalue–0.53) 
The results of the study on the lipid disorders in patients with 
chronic renal failure show that there are significant alterations in the lipid 
profiles of these patients as compared to controls. 
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Triglycerides: 
Our study demonstrated an increase in Triglycerides between cases 
and controls. (147.6mg/dl vs127.8 mg / dl ). This was significant 
statistically. (P values <0.05).This result was in concordance with the 
work done by E.Kimak and team69, in which they demonstrated a 
significant increase in Triglycerides, LDL and Apo-B concentrations.In 
another study, done by Bhagwat.R , Joshi S P and team70, they concluded 
that CRF patients were having marked triglyceridemia of 232 mg / dl as 
compared to controls.(P value less than 0.01) .Another Indian study on 
dyslipidemia in patients with CRF and renal transplantation by B.Shah, 
S.Nair and coworkers71 they demonstrated that triglycerides was elevated 
significantly in CRF patients on conservative management. These results 
shows that hypertriglyceridemia is an important lipid abnormality in 
patients with CRF. Attman P.O, Alaupovic P72stated that  
hypertriglyceridemia  is  the  most common plasma lipid abnormality in 
patients of chronic renal failure. 
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VARIOUS STUDIES ON PROGRESSION OF KIDNEY DISEASE 
AND ASSOCIATED PLASMA LIPID ABNORMALITIES: 
Study Patients 
Number of 
patients 
Follow up Lipidpattern
MDRD CKD 840 2.2 YRS ↓HDL 
Samuelsson O 
et al62 
CKD 73 3.2 YRS ↑TCh, 
↑LDL, 
↑ApoB 
Locatelli et al74 CKD 456 2 YRS No 
relationship 
 
HDL Cholesterol: 
Our study demonstrated a significant decrease in HDL in CRF 
cases when compared with controls (38.8mg/dl vs 54mg/dl) (P value 
0.0001). This was in concordance with the results obtained by Bhagwat R 
and team70 where they found HDL cholesterol to be significantly low. (20 
± 11)mg/ dl( P value less than 0.001) in CRF groups. P.O. Attman et al72 
found decrease in plasma HDL cholesterol concentration in patients with 
CRF. 
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LDL Cholesterol: 
Our study demonstrated an increase in LDL cholesterol between 
cases and controls. (110 mg/dl vs101.6 mg / dl ). This was not significant 
statistically, p value (0.24). This was similar to the study by Bhagwat R 
and Joshi S P70 where, they found that LDL cholesterol in CRF patients 
showed an increase when compared to controls which, is not statistically 
significant. Study by E.Kimak and team69 showed results not comparable 
to our study, where LDL cholesterol showed significant increase among 
CRF patients compared with controls in their study. 
Total Cholesterol: 
Our study demonstrated a decrease in total cholesterol between 
cases and controls. (164 mg/dl vs176.3 mg / dl ). This was not significant 
statistically, p value (0.07). N.D. Vaziri73 concluded that plasma 
cholesterol can be normal or decreased, as occured in our study. E.Kimak 
and coworkers69 in their work on plasma lipoproteins in CRF patients 
concluded that total cholesterol is not increased significantly in patients 
with CRF. P.O. Attmanet al72 in their study showed no significant change 
in levels of total cholesterol. 
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TC/HDLRATIO:  
 Our study demonstrated a increase in the Total cholesterol HDL 
ratio between the cases and the controls (4.3Vs 3.4). This was statistically 
significant (p value <0.05) 
COMPARISON OF LIPID PROFILE BETWEEN OTHER STUDIES 
AND OUR STUDY 
Studies  TGL LDL HDL T 
Shah et 
al 
S 
 
C 
222.78±90.08 
 
121.78±64.89 
109.63±36.51 
 
140.33±23.34 
52.69±16.36 
 
44.22±10.33 
211.33±40.33 
 
184.11±18.79 
Diana 
Mlee 
etal 
S 
 
C 
194.05±106.28 
 
106.28±26.5 
170.148±50.27 
 
131.47±30.93 
38.6±11.6 
 
42.53±7.73 
239.75±61.8 
 
189.14±30.93 
Our 
study 
S 
 
C 
147.68±61.57 
 
127.86±27.23 
110.08±45.10 
 
101.62±23.76 
38.86±8.04 
 
54.04±10.74 
164.02±39.9 
 
176.34±24.37 
S - Study;   C - Control 
Stagewise comparison of C.K.D. and lipid abnormalities: 
We have no study group fitting into stage I and II kidney disease, 
we analyzed the other 3 stages of CKD. The decrease in HDL observed in 
3 group (mean 38.38, 38.40, 39.45) respectively are not statistically 
significant in severity when compared with stages (P>0.05). Similarly 
rise in TGL observed in III IV and V stage of CKD having mean value 
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(121.88, 154.8, 150.59) respectively are not statistically significant in 
severity when compared with stages (P>0.05). The rise in LDL obtained 
in III, IV and V stages of CKD having mean value (111.75, 106.45, 
112.7) respectively, on comparison are not statistically significant 
(P>0.05). The decrease in Total Cholesterol obtained in III, IV and V 
stages of CKD having mean value (156.75,162.80,167.77) respectively, 
on comparison are not statistically significant. The rise in Total 
cholesterol HDL ratio obtained in III, IV and V stages of CKD having 
mean value (4.08,4.36,4.37) respectively, on comparison are not 
statistically significant.  Though we found lipid abnormalities in form of 
↑TGL ↑ LDL, ↓ HDL,↓TC,↑TC/HDL ratio in study group in all stage of 
CKD, this alteration is not statistically significant in severity on 
comparison by using this statistical package (S.P.S.S) in form of paired 
‘t’ test and anova test. 
According to the E. Kimak and coworkers69 study, the increase in 
TG,TC, LDL & ↓ HDL levels were significant in early stages of kidney 
disease and in end stage kidney disease, there is not much alteration in 
lipid profile. 
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Stagewise comparison of stages of CKD and Categories of Lipids 
The lipid pattern abnormalities are classified according to ATP III 
Classification and they are compared to Stages of CKD.  
HDL cholesterol was divided into low and high and compare to 
stage III, IV, V of CKD, >60% had low HDL values, the comparison was 
not statistically significant.(p value 0.59 by chi square). 
TGL was classified into Normal, Borderline High, High and Very 
High and compared to the to stage III, IV, V of CKD, maximum number 
was in  normal group, next to that was high group, but the comparison 
was not statistically significant(p value 0.48 by chi- square) 
LDL was classified into Optimal, Near Optimal, Borderline High, 
High and Very High and compared to the stage III, IV, V of CKD, 
percentage of optimal group was the maximum, next to that was the 
Borderline high group. But the comparison was not statistically 
significant (p value 0.28 by chi- square) 
TC was classified into Desirable, Borderline High, High and 
compared to the stage III, IV, V of CKD, percentage of Desirable was the 
maximum and next to that was the Borderline High group, but the 
comparison was not statistically significant (p value 0.09 by chi- square) 
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Hence it is stated from our study that there is no direct relationship 
between derangement of lipid abnormalities and staging of CKD. 
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CONCLUSION 
Lipid abnormalities are common in CKD and are found to occur in 
all stages of CKD. 
HDL – C  shows  a  statistically  significant  decrease  in  CKD 
patients compared with controls and it is the predominant lipid pattern 
abnormality in our study. 
Triglycerides shows statistically significant increase in CKD cases 
when compared with controls. 
LDL–C was increased in CKD patients but it is not statistically 
significant when compared with controls. 
The TC/HDL ratio was increased CKD patients and it is found to be 
statistically significant 
Total Cholesterol is decreased in CKD patients but, it is not 
statistically significant when compared with controls. 
The lipid abnormalities started to occur even in the earlier stages of 
CKD. 
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The severity of chronic kidney disease did not correlate with the 
severity of lipid abnormalities and it was found to be statistically 
insignificant. 
Finally, because the lipid abnormalities in chronic renal failure 
predisposes to atherosclerosis and accelerates the progression of the renal 
failure it is worthwhile detecting and treating hyperlipidemia in CKD 
patients. 
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ACRONYMS 
ABCA1 _ ATP-binding cassette subfamily A member 1; 
ABCG1 _ ATP-binding cassette subfamily G member 1 
ACAT _ Acyl CoA :cholesterol acyltransverase 
ACE _ Angiotensin converting enzyme 
ACVD _ Atherosclerotic cardio vascular disease 
ATP – Adult treatment panel 
ARB – Angiotensin receptor blocker 
CETP – Cholesteryl ester transfer protein 
CM – Chylomicron 
CHD _ Coronary heart disease 
CKD – Chronic kidney disease 
CRF – Chronic renal failure 
ESRD – End stage renal disease 
GFR – Glomerular filtration rate 
HDL – High density lipoprotein 
HL – Hepatic lipase 
IDL – Intermediate density lipoprotein 
LDL – Low density lipoprotein 
LCAT – Lecithin cholesterol acyl transferase 
LPL – Lipoprotein lipase 
MDRD _ Modified diet in renal disease 
MTP – Microsomal transfer protein 
NS – Nephrotic syndrome 
SRB1 _ Scavenger receptor B1 
TC – Total cholesterol 
TGL – Triglycerides 
VLDL – Very low density lipoprotein 
 
PROFORMA 
 
Name Age                                  Sex 
IP Number Occupation                        
Address 
 
Presenting complaints 
Oliguria  
Pedaledema 
Nausea,  
vomiting  
Pruritus 
Hiccups 
Facial puffiness  
Dyspnea 
Past history  
Diabetes  
Hypertension  
TIA 
Stroke 
Drug history 
Thiazides,    Betablockers,   Steroids 
Family history 
H/o Diabetes,  Hypertension,   Hyper lipidemia 
Personal history 
Smoking   Alcoholism 
General examination 
Pallor  
Icterus         
Cyanosis  
Clubbing  
Lymphadenopathy  
Pedal Edema  
Facial puffiness  
JVP 
Evidence for hyperlipidemia 
Xanthelasma:  
Arcus:  
Tendinous (or) Eruptive xanthoma: 
 
 
Height :    
Weight : 
Vitals  Pulse   BP  RR  Temp 
 
CVS 
 
RS 
 
Abdomen 
 
CNS 
 
Investigations 
Urine 
Albumin,    Sugar,    Deposits 
Blood 
Sugar  
Hb,     TC,     DC 
 
Renal function tests 
 Blood Urea 
 Serum creatinine 
USG abdomen for kidney size: 
Fasting lipid profile: 
 Total cholesterol,  
 HDL,  
 LDL,  
 Triglycerides,  
 Total Cholesterol/ HDL ratio: 
FINAL DIAGNOSIS 
 
Sl No. NAME AGE SEX WT.
SERUM 
CREATININE
μmol/l 
CREATININE
CLEARANCE
ml/min. STAGING
HDL 
mg/dl
LDL 
mg/dl
TGL 
mg/dl 
TC
mg/dl TC/HDL
1 KULANDAISAMY 53 M 65 800 8.7 5 37 144 118 208 5.6
2 JANAGI 62 F 55 290 15.4 4 39 86 253 179 4.5
3 DURAI 51 M 60 836 7.8 5 46 62 148 138 3
4 PERIYANAYAGI 60 F 60 1188 4.2 5 53 157 175 248 4.7
5 THIRUVENGADAM 54 M 62 783 8.4 5 30 124 226 114 3.8
6 VARADARAJAN 39 M 53 239 27.5 4 49 110 90 180 3.7
7 MALAISELVI 42 F 53 504 10.8 5 57 95 161 181 3.1
8 IMAM 43 M 42 336 14.9 5 28 88 69 133 4.7
9 PAVAYEE 23 F 50 203 30.1 3 30 59 106 113 3.6
10 KANNIYAMMAL 55 F 49 1017 4.3 5 31 66 99 121 3.7
11 ALEXANDER 38 M 65 327 24.9 4 51 75 155 160 3.1
12 JAGADAMBAL 57 F 48 451 9.2 5 46 133 138 193 4.2
13 MANGAMMAL 60 F 47 212 18.5 4 40 57 103 82 2
14 SARADHA 26 F 46 318 17.2 4 40 151 119 180 4.5
15 RAJALAKSHMI 38 F 48 830 6.2 5 38 171 190 136 3.5
16 AYYADURAI 55 M 52 362 15 4 42 77 102 107 2.5
17 KALIYAMMAL 51 F 45 239 17.5 4 46 80 105 55 1.1
18 NANDINI 42 F 59 221 27.3 4 26 97 106 148 5.7
MASTER CHART OF STUDY GROUP
Sl No. NAME AGE SEX WT.
SERUM 
CREATININE
μmol/l 
CREATININE
CLEARANCE
ml/min. STAGING
HDL 
mg/dl
LDL 
mg/dl
TGL 
mg/dl 
TC
mg/dl TC/HDL
19 ANGURAJ 67 M 60 239 22.5 4 38 53 150 124 3.2
20 MANIKANDAN 53 M 49 1414 3.6 5 40 85 264 181 4.5
21 SELVI 31 F 57 539 12 5 41 57 134 149 3.6
22 MARIMUTHU 50 M 67 203 36.5 3 36 89 85 145 4
23 GOVINDASAMY 61 M 52 1502 3.4 5 41 119 192 127 3
24 GANESAN 45 M 65 839 9 5 33 110 254 158 4.7
25 PERIYAKKA 42 F 60 283 21.7 4 50 125 203 219 4.4
26 PRAKASH 18 M 42 1635 3.8 5 42 176 236 176 4.2
27 MADHAYAN 62 M 65 256 24.3 4 44 70 278 173 3.9
28 PERIYASAMY 62 M 67 345 18.6 4 33 44 146 109 3.3
29 CHELLAPPAN 56 M 63 274 23.7 4 34 217 188 218 6.4
30 ARUNACHALAM 54 M 60 203 31.2 3 46 131 103 201 4.3
31 NADEASAN 63 M 59 185 30.2 3 42 147 142 166 3.9
32 RANGASAMY 59 M 54 256 21 4 24 60 106 108 4.5
33 VIRUDAMBAL 64 F 54 611 7 5 55 38 36 111 2
34 SELVARAJ 30 M 59 513 15.5 4 38 176 206 178 4.7
35 KANNIYAPPAN 42 M 62 248 30.1 3 36 168 186 172 4.7
36 KARUPPASAMY 45 F 64 212 29.9 4 32 200 226 192 6
37 KUPPUSAMY 52 M 61 309 21.3 4 38 134 75 190 5
Sl No. NAME AGE SEX WT.
SERUM 
CREATININE
μmol/l 
CREATININE
CLEARANCE
ml/min. STAGING
HDL 
mg/dl
LDL 
mg/dl
TGL 
mg/dl 
TC
mg/dl TC/HDL
38 VALLI 59 F 44 186 20 4 40 201 94 263 6.5
39 ARULMURUGAN 32 M 54 902 7.9 5 30 107 84 159 5.3
40 MANI 54 M 72 203 37.5 3 54 126 105 204 3.7
41 DHANAPAL 28 M 54 1176 6.3 5 36 154 128 169 4.7
42 NAGAPPAN 65 M 48 698 6.3 5 27 76 96 126 4.6
43 AMMASI 69 M 67 248 23.6 4 34 46 140 161 4.7
44 SAKTHIVEL 42 M 65 265 29.5 4 30 70 251 153 5.1
45 NALLUSAMY 60 M 70 221 31.1 3 32 99 148 104 3.2
46 RAJAPPAN 42 M 67 194 41.6 3 31 75 100 129 4.1
47 IRULLAPPAN 50 M 60 893 7.4 5 37 144 118 208 5.6
48 CHINNAMAYIL 17 F 42 734 7.3 5 48 138 96 208 4.3
49 PERUMAN 40 M 77 1250 7.6 5 30 120 273 209 6.9
50 AYYASAMI 56 M 45 387 12 5 42 117 78 177 4.2
